Atorvastatin for Reduction of 28-day Mortality in COVID-19: RCT
Status:
Active, not recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This randomized placebo-controlled double-blinded clinical trial aims to test the efficacy of
administering atorvastatin 40 mg to hospitalized COVID-19 patients for 28 days on the
all-cause 28-day mortality.